Literature DB >> 15841646

Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma.

Rafael F Martín-García1.   

Abstract

BACKGROUND: Some patients with invasive cutaneous squamous cell carcinoma are either not adequate surgical candidates or present with lesions in cosmetically sensitive areas in which a surgical procedure might result in an apparent and/or a cosmetically unacceptable scar.
OBJECTIVE: To evaluate the effectiveness of imiquimod 5% cream in the treatment of an invasive squamous cell carcinoma in the nose of a young man.
METHODS: Imiquimod 5% cream was applied to the lesion five times a week for 12 weeks.
RESULTS: Complete clinicopathologic tumor clearance and an excellent cosmetic result were achieved after 12 weeks of imiquimod treatment.
CONCLUSION: Imiquimod 5% cream may represent a reasonably effective alternative for the management of invasive squamous cell carcinoma in selected patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15841646     DOI: 10.1111/j.1524-4725.2005.31093

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  10 in total

1.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

Review 2.  Emerging Therapies for Scar Prevention.

Authors:  Lisa Block; Ankush Gosain; Timothy W King
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-10-01       Impact factor: 4.730

Review 3.  Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.

Authors:  Antona J Wagstaff; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles.

Authors:  Jeremy S Blum; Caroline E Weller; Carmen J Booth; Imran A Babar; Xianping Liang; Frank J Slack; W Mark Saltzman
Journal:  Drug Deliv Transl Res       Date:  2011-10-01       Impact factor: 4.617

5.  Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin.

Authors:  Susan J Huang; Dirkjan Hijnen; George F Murphy; Thomas S Kupper; Adam W Calarese; Ilse G Mollet; Carl F Schanbacher; Danielle M Miller; Chrysalyne D Schmults; Rachael A Clark
Journal:  J Invest Dermatol       Date:  2009-06-11       Impact factor: 8.551

Review 6.  [Precancerous and early invasive carcinomas: non-surgical treatment of head and facial skin].

Authors:  E Haneke
Journal:  HNO       Date:  2009-04       Impact factor: 1.284

7.  Laser immunotherapy for cutaneous squamous cell carcinoma with optimal thermal effects to enhance tumour immunogenicity.

Authors:  Min Luo; Lei Shi; Fuhe Zhang; Feifan Zhou; Linglin Zhang; Bo Wang; Peiru Wang; Yunfeng Zhang; Haiyan Zhang; Degang Yang; Guolong Zhang; Wei R Chen; Xiuli Wang
Journal:  Int J Hyperthermia       Date:  2018-04-16       Impact factor: 3.914

8.  Effects of imiquimod and low-intensity laser (λ660 nm) in chemically induced oral carcinomas in hamster buccal pouch mucosa.

Authors:  Juliana S de C Monteiro; Susana C P S de Oliveira; João Alves Reis Júnior; Clarissa Araújo Silva Gurgel; Suzana C O Machado de Souza; Antônio Luiz Barbosa Pinheiro; Jean Nunes dos Santos
Journal:  Lasers Med Sci       Date:  2012-09-01       Impact factor: 3.161

9.  Management of keloids and hypertrophic scars: current and emerging options.

Authors:  Gerd G Gauglitz
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-04-24

10.  Advances in the use of topical imiquimod to treat dermatologic disorders.

Authors:  Francesco Lacarrubba; Maria Rita Nasca; Giuseppe Micali
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.